Altimmune Inc (ALT)

Apr 11, 2025

Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com

Apr 11, 2025

Apr 10, 2025

Altimmune's US$42m Market Cap Fall Books Insider Losses - Yahoo

Apr 10, 2025

Apr 09, 2025

Coulter Partners places seasoned biopharmaceutical industry executives to Altimmune Board of Directors - Hunt Scanlon Media

Apr 09, 2025

Apr 08, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com Canada

Apr 08, 2025

Apr 08, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook - Investing.com

Apr 08, 2025

Apr 06, 2025

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders - ACCESS Newswire

Apr 06, 2025

Apr 04, 2025

H.C. Wainwright maintains Buy rating on Altimmune stock By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 04, 2025

H.C. Wainwright maintains Buy rating on Altimmune stock - Investing.com India

Apr 04, 2025

Apr 03, 2025

8 Analysts Assess Altimmune: What You Need To Know - Benzinga

Apr 03, 2025

Apr 03, 2025

Altimmune’s Pemvidutide: A Promising Catalyst with Blockbuster Potential and Strong Financial Backing - TipRanks

Apr 03, 2025

Apr 03, 2025

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN

Apr 03, 2025

Mar 31, 2025

PharmAthene stock hits 52-week low at $5.1 amid challenges By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com

Mar 31, 2025

Mar 31, 2025

Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Mar 31, 2025

Mar 28, 2025

Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

Mar 28, 2025

Mar 22, 2025

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo

Mar 22, 2025

Mar 19, 2025

Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN

Mar 19, 2025

Mar 19, 2025

10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey

Mar 19, 2025

Mar 17, 2025

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha

Mar 17, 2025

Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada

Mar 17, 2025

Mar 17, 2025

ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 17, 2025

Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa

Mar 17, 2025

Mar 16, 2025

Altimmune rises as buyout rumors follow R&D updates - MSN

Mar 16, 2025

Mar 15, 2025

Altimmune CFO Gregory Weaver purchases $51,996 in stock By Investing.com - Investing.com Australia

Mar 15, 2025

Mar 14, 2025

Altimmune Outlines Pemvidutide Plans In MASH And Beyond - insights.citeline.com

Mar 14, 2025

Mar 14, 2025

Altimmune soars amid takeover speculation - MSN

Mar 14, 2025

Mar 14, 2025

Altimmune stock rises amid buyout and R&D news(ALT:NASDAQ) - Seeking Alpha

Mar 14, 2025

Mar 14, 2025

(ALT) Trading Advice - Stock Traders Daily

Mar 14, 2025

Mar 14, 2025

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Benzinga

Mar 14, 2025

Mar 14, 2025

Stifel maintains Buy on Altimmune stock, $18 price target - Investing.com India

Mar 14, 2025

Mar 14, 2025

Stifel maintains Buy on Altimmune stock, $18 price target By Investing.com - Investing.com UK

Mar 14, 2025

Mar 14, 2025

Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions - TradingView

Mar 14, 2025

Mar 14, 2025

Altimmune CFO Gregory Weaver purchases $51,996 in stock - Investing.com India

Mar 14, 2025

Mar 14, 2025

Citizens JMP reiterates Altimmune stock with $25 target By Investing.com - Investing.com South Africa

Mar 14, 2025

Mar 14, 2025

Citizens JMP reiterates Altimmune stock with $25 target - Investing.com

Mar 14, 2025

Mar 14, 2025

Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M - Endpoints News

Mar 14, 2025

Mar 14, 2025

Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook - TipRanks

Mar 14, 2025

Mar 13, 2025

Altimmune to test obesity drug for alcohol use disorder and related health conditions - TradingView

Mar 13, 2025

Mar 13, 2025

Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions - TradingView

Mar 13, 2025

Mar 13, 2025

Unpartnered Obesity Assets Are Becoming Slim Pickings For Pharma - insights.citeline.com

Mar 13, 2025

Mar 12, 2025

SBI Securities Co. Ltd. Acquires New Shares in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Mar 12, 2025

Mar 10, 2025

Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide - Investing.com Australia

Mar 10, 2025